Acumen Pharmaceuticals Inc.
4435 North First Street,
31 articles with Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s disease (AD), today reported financial results for the quarter ended June 30, 2021 and provided recent business highlights.
7/7/2021The long weekend didn't slow down the IPO train barreling down the tracks. More life sciences companies announced and closed their initial public offerings, bringing millions more to their coffers.
The first half of 2021 has seen a flurry of IPOs as companies make the move to become publicly traded. The trend continued, as biopharma companies hit the stock exchange this week.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what Acumen believes to be a key underlying cause of Alzheimer’s disease, announced the pricing of its upsized initial public offering of 9,999,999 shares of common stock at a public offering price of $16.00 per share.
Acumen Pharmaceuticals Inc. Announces Milestone Achievement In Collaboration With Merck & Co., Inc. (Jobs)
Acumen Pharmaceuticals Inc. Announces Amended Agreement With Merck & Co., Inc. To Include Exclusive Diagnostic Rights